Details of the Drug

General Information of Drug (ID: DMO3QAZ)

Drug Name

DNL310

Indication

Disease Entry	ICD 11	Status	REF
Mucopolysaccharidosis II	5C56.31	Phase 2/3	[1]
------------------------------------------------------------------------------------

Drug Type

Enzyme replacement

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05371613) A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Denali